Celldex falls after two probable anaphylaxis cases in trials

By Reuters News14:58 (UTC), 22 September 2026 Updated

** Shares of Celldex Therapeutics CLDX.O down 12.8% to $33.07, set for its biggest one-day fall in just over a year

** The biotech company says its experimental drug barzolvolimab met main and all key secondary endpoints in two late-stage studies for chronic spontaneous urticaria

** Chronic spontaneous urticaria is a condition that causes recurring itchy hives and swelling

** Analysts pointed to safety concerns and efficacy over probable anaphylaxis cases reported in trials weighing on shares

** CLDX had gained as much as 45% to $55 in premarket trading following trial results

** Co plans to file for U.S. FDA approval in 2027

** Fourteen of 15 brokerages rate the stock "buy" or higher, one "hold"; their median PT is $56 — data compiled by LSEG

** Including session moves, CLDX stock up over 21% YTD

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.